Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramBusiness Wire • Tuesday
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyBusiness Wire • Monday
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver MeetingBusiness Wire • 11/15/24
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay OffSeeking Alpha • 11/05/24
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 10/31/24
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 10/31/24
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024Business Wire • 10/17/24
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024Business Wire • 10/15/24
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceBusiness Wire • 10/03/24
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersBusiness Wire • 09/09/24
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/22/24
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?Zacks Investment Research • 08/06/24
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/01/24
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline OpportunitiesBusiness Wire • 08/01/24
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell EngagersBusiness Wire • 08/01/24
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024Business Wire • 07/18/24
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And HepatitisSeeking Alpha • 07/17/24
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionBusiness Wire • 06/26/24
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentBusiness Wire • 06/05/24